A multicentre, randomised, double-blind (sponsor-unblinded), placebo-controlled study with open label extension to investigate the safety and tolerability, pharmacokinetics, pharmacodynamics, and efficacy of GSK2982772 in subjects with active ulcerative colitis
- Registry ID
- EUCTR2016-001833-29
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- GlaxoSmithKline Research & Development Ltd
- Start date
- 2016-09-07
- Completion date
- 2019-06-17
- Last update
- 2026-08-16
Conditions
- Active ulcerative colitis
Summary
To investigate the safety and tolerability of 60 mg three times daily doses of GSK2982772 in subjects with moderate to severe ulcerative colitis.
Locations
- , , Sweden
- , , UK
- , , Poland
- , , Netherlands
View on source registry